ÈËÆÞÖгöÊÓƵ

Huntsman Cancer Institute (HCI) and (U of U) welcome Sachin Apte, MD, MS, MBA. Apte will serve as chief clinical officer of HCI and physician-in-chief of the cancer hospital. Selected following an extensive national search, Apte begins his appointment on February 8, 2021.

"Dr. Apte will lead HCI’s clinical efforts at a time when we are poised to dramatically expand our impact for the patients and communities we serve," says , CEO of HCI. "He will advance our efforts to innovate clinical programs and care delivery, enhance quality of care, and develop clinical talent. I look forward to his leadership during this critical time of growth and transformation."

Apte joins HCI from Moffitt Cancer Center where he served as associate chief medical officer. Apte is a board-certified gynecologic oncologist who previously served as chair of the department of gynecologic oncology. He obtained his bachelor of science in chemical engineering from Cornell ÈËÆÞÖгöÊÓƵ and his medical degree from The Ohio State ÈËÆÞÖгöÊÓƵ. He completed a fellowship in gynecologic oncology at M.D. Anderson Cancer Center while also obtaining his master of science in cancer biology from the ÈËÆÞÖгöÊÓƵ of Texas ÈËÆÞÖгöÊÓƵ Science Center at Houston. Apte obtained an MBA from the ÈËÆÞÖгöÊÓƵ of Tennessee in 2012.

Apte will oversee oncology work of HCI and U of U ÈËÆÞÖгöÊÓƵ to deliver high-quality cancer care and prevention programs across the Mountain West. He will collaborate with HCI and U of U ÈËÆÞÖгöÊÓƵ colleagues to direct all aspects of clinical cancer services at HCI’s flagship hospital in Salt Lake City, community clinics, and other offerings that bring care and screenings to communities across the region or directly to patients in their homes. This includes oversight and planning of a major clinical expansion underway at HCI, the Kathryn F. Kirk Center for Comprehensive Cancer Care and Women’s Cancers. He will also serve as a professor of obstetrics and gynecology at U of U ÈËÆÞÖгöÊÓƵ.

"His experience in operational efficiency, clinical quality, partnership and business development, and physician recruitment will be an asset to HCI and U of U ÈËÆÞÖгöÊÓƵ. Dr. Apte will build upon the excellent foundation we have established in Utah," says Thomas Miller, MD, chief medical officer at U of U ÈËÆÞÖгöÊÓƵ.

"I am honored to have this extraordinary opportunity. Since its founding, HCI has demonstrated incredible scientific impact, community benefit, and growth. There is a palpable collaborative culture, driven to innovate to eradicate cancer. I am excited to work with this dynamic and forward-thinking team to achieve the organization’s immense potential," Apte says.

Apte succeeds John Ward, MD, who has served in this position in an interim capacity since April 2019. Ward will continue his service at HCI, including his clinical program caring for breast cancer patients and other key leadership roles.